Research programme: Src kinase inhibitors - Athenex

Drug Profile

Research programme: Src kinase inhibitors - Athenex

Alternative Names: KX-2377

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Kinex Pharmaceuticals
  • Developer Athenex
  • Class Small molecules
  • Mechanism of Action Src-Family kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Sensorineural hearing loss

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for research development in Sensorineural hearing loss in USA
  • 23 Jul 2007 US FDA approves IND application for KX2 391 in patients with solid tumours or lymphoma
  • 25 Jun 2007 Kinex Pharmaceuticals files an IND with the US FDA for a phase I trial of KX2 391 in patients with solid tumours or lymphoma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top